Woebot Health Names Matt Borowiecki Chief Financial Officer

Woebot Health today announced that it has appointed Matt Borowiecki as its Chief Financial Officer. A member of the senior management team, Borowiecki will lead the company’s financial operations and strategy, including management and financial reporting, budgeting and long-term financial planning, and will also manage its capital structure. He reports to Chief Executive Officer Michael Evers.

Matt Borowiecki has more than 20 years of global experience in finance, strategy and corporate development across healthcare, insurance and financial services, and has managed acquisitions, divestitures, joint ventures and debt and equity financings totaling more than $60 billion of value. Before joining Woebot Health, Borowiecki was the Chief Financial Officer at Biofourmis, a technology-enabled care delivery and digital therapeutics company. In that position, he led Biofourmis’ financial operations as it scaled revenue, customers and employees and surpassed unicorn status.

Before that, Borowiecki was the Head of Capital Transactions and Structuring at MassMutual Financial Group. His healthcare industry experience dates to 2011 when he joined Aetna as its Director of Corporate Development and Enterprise Strategic Planning. Previously Borowiecki held positions of increasing responsibility at leading investment banks Morgan Stanley, Lehman Brothers and UBS.

“Matt’s deep understanding of the healthcare industry and investment acumen will be instrumental as we mature our operations and move to the next level of our company’s growth,” said Evers. “His strategic experience is complemented by a deep compassion and commitment to helping people access the mental health care they need. We’re delighted he’s joined at this very pivotal moment.”

“The last few years have placed a spotlight on mental health, while the last few months have seen incredible advances in technologies that can play a role in changing the way we deliver care,” said Borowiecki. “We have the opportunity to really make a difference in patients’ lives, and that’s extremely motivating.”

Borowiecki holds a Master of Business Administration degree from the Tuck School of Business at Dartmouth and a Bachelor of Arts degree in Economics from Kenyon College. He is an avid traveler who has visited 47 countries and dependencies and 44 U.S. states.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.